Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

Blood (2025) 146 (Supplement 1): 6094.

https://doi.org/10.1182/blood-2025-6094

Published: 2025

Journal Articles

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Colleen Kelly, Morgan Paul, Wendy London, Rahela Aziz-Bose, Puja Umaretiya, Erica Esrick, Victoria Coleman-Cowger, Gary Schiller, Mehrdad Abedi, Joseph Antin, Mary Horowitz, Neena Kapoor, Edmund Waller, Sonali Chaudhury, Mary Eapen, Mark Walters, David Williams, Kira Bona

Blood (2025) 146 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2025-6224

Published: 2025

Journal Articles

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

Blood (2025) 146 (Supplement 1): 2532.

https://doi.org/10.1182/blood-2025-2532

Published: 2025

Journal Articles

Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507

Blood (2025) 146 (Supplement 1): 164.

https://doi.org/10.1182/blood-2025-164

Published: 2025

Journal Articles

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Blood (2024) 144 (Supplement 1): 513.

https://doi.org/10.1182/blood-2024-204888

Published: 2024

Journal Articles

One’s expectations for normality

Mary Eapen

Blood (2024) 144 (14): 1469–1470.

https://doi.org/10.1182/blood.2024025822

Published: 2024

Journal Articles

Choosing donors in clinical practice

Mary Eapen

Blood (2024) 144 (3): 248–249.

https://doi.org/10.1182/blood.2024024970

Published: 2024

Journal Articles

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Blood (2023) 142 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2023-192022

Published: 2023

Journal Articles

Gene Therapy Expressing Platelet-Derived Factor VIII for Correction of Hemophilia Α with a History of Inhibitors

David A. Wilcox, Myriam Armant, Lynn Malec, Qizhen Shi, Bryon D. Johnson, Huiqing Xu, Lily M. Du, Lisa J. Duffy, Frederic D. Bushman, James H. Jerkins, Peiman Hematti, Ruta Brazauskas, Shawn M. Jobe, Parameswaran N. Hari, Mary Eapen

Blood (2023) 142 (Supplement 1): 2249.

https://doi.org/10.1182/blood-2023-172845

Published: 2023

Journal Articles

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

Mary Eapen, Joseph Antin, Jakub Tolar, Sally Arai, Mitchell Horwitz, Jainqun Kou, Eric Leifere, John M. McCarty, Ryotaro Nakamura, Michael A. Pulsipher, Mary M. Horowitz, H Joachim Deeg

Blood (2023) 142 (Supplement 1): 235.

https://doi.org/10.1182/blood-2023-178093

Published: 2023

Journal Articles

To treat with curative intent or modify disease?

Mary Eapen

Blood (2023) 141 (1): 4–5.

https://doi.org/10.1182/blood.2022017792

Published: 2023

Journal Articles

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

Ashley V Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, Jim A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S Kean, K. Scott Baker, Lauri S Burroughs, Jeffrey R. Andolina, Michael B Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh

Blood (2021) 138 (Supplement 1): 748.

https://doi.org/10.1182/blood-2021-145629

Published: 2021

Journal Articles

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation

Andrew St. Martin, Kyle Hebert, Arnaud Serret-Larmande, Vianney Jouhet, Emily Hughes, Jason Paul Stedman, Thomas DeSain, Danielle Pillon, Jessica Lyons Carpenter, Patricia Steinert, Paul Avillach, Mary Eapen

Blood (2021) 138 (Supplement 1): 410.

https://doi.org/10.1182/blood-2021-150912

Published: 2021

Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Blood (2021) 138 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2021-145527

Published: 2021

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Muna Qayed, Kwang Woo Ahn, Carrie L. Kitko, Mariam H. Johnson, Nirali N. Shah, Christopher Dvorak, Karin Mellgren, Brian D. Friend, Michael R. Verneris, Wing Leung, Jacek Toporski, John Levine, Joseph Chewning, Alan Wayne, Urvi Kapoor, Brandon Triplett, Kirk R. Schultz, Gregory A. Yanik, Mary Eapen

Blood (2021) 137 (7): 983–993.

https://doi.org/10.1182/blood.2020009342

Published: 2021

Journal Articles

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Blood (2021) 137 (3): 420–428.

https://doi.org/10.1182/blood.2020007535

Published: 2021

Includes: Supplemental data

Journal Articles

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Rebecca A. Marsh, Soyoung Kim, Kyle Hebert, Christopher C. Dvorak, MD, Victor Aquino, MD, K. Scott Scott Baker, MD MS, Deepak Chellapandian, MD, Blachy Davila, MD, Christine Duncan, MD, Michael J. Eckrich, MD MPH, George E. Georges, MD, Timothy S. Olson, MD PhD, Michael A Pulsipher, MD, Shalini Shenoy, MD, Elizabeth Stenger, MD, Mark Vander Lugt, MD, Lolie C. Yu, MD, Andrew Gennery, MD, Mary Eapen, MBBS, MS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139930

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

One’s expectations for normality

Choosing donors in clinical practice

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Gene Therapy Expressing Platelet-Derived Factor VIII for Correction of Hemophilia Α with a History of Inhibitors

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

To treat with curative intent or modify disease?

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only